New hope or hype? brain cancer drug trial aims to boost immune attack
NCT ID NCT02852655
First seen Mar 31, 2026 · Last updated May 16, 2026 · Updated 2 times
Summary
This early-phase trial tests the immunotherapy drug pembrolizumab in 60 adults with recurrent glioblastoma, an aggressive brain cancer. The main goal is to see how the drug affects immune cells inside the tumor and to check for side effects. This study is not a cure but aims to gather important information for future treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAIN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Huntsman Cancer Institute
Salt Lake City, Utah, 84112, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Memorial Sloan-Kettering Cancer
New York, New York, 10065, United States
-
UT, MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
University of California, Los Angeles
Los Angeles, California, 90095, United States
-
University of California, San Francisco
San Francisco, California, 94143-0372, United States
Conditions
Explore the condition pages connected to this study.